A detailed history of Lazard Asset Management LLC transactions in Cytosorbents Corp stock. As of the latest transaction made, Lazard Asset Management LLC holds 1,090 shares of CTSO stock, worth $991. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,090
Previous 938 16.2%
Holding current value
$991
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$0.86 - $1.07 $130 - $162
152 Added 16.2%
1,090 $1,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.94 $1,013 - $1,819
938 New
938 $1,000
Q4 2021

Feb 09, 2022

SELL
$4.05 - $8.11 $21,752 - $43,558
-5,371 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.0 - $9.71 $30,513 - $42,325
4,359 Added 430.73%
5,371 $43,000
Q2 2021

Aug 12, 2021

SELL
$7.55 - $9.42 $28,818 - $35,956
-3,817 Reduced 79.04%
1,012 $7,000
Q4 2020

Feb 11, 2021

BUY
$7.65 - $8.98 $36,941 - $43,364
4,829 New
4,829 $38,000

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $39.7M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.